New Hypothesis on Pathogenesis of Ovarian Cancer Lead to Future Tailored Approaches
Open Access
- 25 August 2013
- journal article
- review article
- Published by Wiley in BioMed Research International
- Vol. 2013, 1-13
Abstract
In the last decades, management of epithelial ovarian cancer (EOC) has been based on the staging system of the International Federation of Gynecology and Obstetrics (FIGO), and different classifications have been proposed for EOC that take account of grade of differentiation, histological subtype, and clinical features. However, despite taxonomic efforts, EOC appears to be not a unique disease; its subtypes differ for epidemiological and genetic risk factors, precursor lesions, patterns of spread, response to chemotherapy, and prognosis. Nevertheless, carboplatin plus paclitaxel combination represents the only standard treatment in adjuvant and advanced settings. This paper summarizes theories about the classification and origin of EOC and classical and new prognostic factors. It presents data about standard treatment and novel agents. We speculate about the possibility to create tailored therapy based on specific mutations in ovarian cancer and to personalize prevention.Keywords
This publication has 88 references indexed in Scilit:
- Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian CancerJAMA, 2011
- Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigmHuman Pathology, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- PARP Inhibitor Treatment in Ovarian and Breast CancerCurrent Problems in Cancer, 2011
- The molecular pathogenesis of hereditary ovarian carcinomaCancer, 2010
- Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethalCancer, 2010
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and MortalityJAMA, 2010
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovaryThe Journal of Pathology, 2010
- Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 2004
- Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancerThe Journal of Pathology, 2001